摘要
血小板减少症为临床常见的疾病,可见于血液系统疾病与非血液系统疾病.随着对促血小板生成药物研究的深入,血小板生成素受体激动剂（TPORA）罗米司亭及艾曲泊帕的临床应用,可有效提高患者血小板计数,为治疗血小板减少症提供新的治疗方法.笔者拟就TPORA的作用机制、其在血液系统疾病及肝病相关的血小板减少症中的临床应用的进展进行综述.
Thrombocytopenia is a common clinical disorder,which could be found in hematological and non-hematological diseases.With significant advances in thrombopoietic agents,the application of thrombopoietin receptor agonist （TPORA）,romiplostim and eltrombopag,could effectively increase the platelet count of patients,and provide a new treatment for thrombocytopenia.This article review the literatures on the mechanisms and clinical use of TPORA in hematological disorders and thrombocytopenia related to hepatopathy.
出处
《国际输血及血液学杂志》
CAS
2014年第6期584-588,共5页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金资助项目（81270581）
